Seres Therapeutics (MCRB) Tops Q2 EPS by 277c
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of $0.47, $2.77 better than the analyst estimate of ($2.30). Revenue for the quarter came in at $736 thousand versus the consensus estimate of $358 thousand.
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA maintains underperform ratings on six BDC stocks
- Nuvectis Pharma (NVCT) files $200M mixed shelf
- OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
